Catalent, Inc.
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Techno…
Drug Manufacturers - Specialty & Generic
US, Somerset [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q2 | Q3 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | 1.00 | 2.51 | 2.48 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | -0.99 | 45.12 | 45.57 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q2 | Q3 | Δ in % | |
|---|---|---|---|---|
| Book Value | -2.06 | 19.84 | 20.26 | |
| Cash | -29.26 | 0.89 | 1.26 | |
| Capex | 21.28 | -0.41 | -0.52 | |
| Free Cash Flow | 244.44 | -0.34 | 0.10 | |
| Revenue | 4.88 | 5.90 | 5.63 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q2 | Q3 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | 27.68 | 0.21 | 0.17 | |
| Operating Margin | -1.30 | -0.02 | -0.02 | |
| ROA | 50.43 | -0.01 | -0.02 | |
| ROE | 49.94 | -0.03 | -0.06 | |
| ROIC | -11.53 | < 0.005 | < 0.005 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of CTLT is permitted for members.
5
Growth
The "Growth Entry" for the Focus of CTLT is permitted for members.
6
Leverage & Liquidity